CLOVIS ONCOLOGY INC's ticker is CLVS and the CUSIP is 189464100. A total of 165 filers reported holding CLOVIS ONCOLOGY INC in Q2 2020. The put-call ratio across all filers is 0.78 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $738,000 | -41.7% | 620,203 | -11.7% | 0.02% | -39.3% |
| Q2 2022 | $1,265,000 | -11.4% | 702,704 | -0.5% | 0.03% | +12.0% |
| Q1 2022 | $1,427,000 | -25.4% | 706,216 | -0.0% | 0.02% | -24.2% |
| Q4 2021 | $1,914,000 | -35.1% | 706,336 | +6.8% | 0.03% | -38.9% |
| Q3 2021 | $2,949,000 | -25.9% | 661,191 | -3.6% | 0.05% | -25.0% |
| Q2 2021 | $3,979,000 | -16.0% | 685,981 | +1.7% | 0.07% | -20.0% |
| Q1 2021 | $4,737,000 | +40.2% | 674,743 | -4.2% | 0.09% | +30.4% |
| Q4 2020 | $3,379,000 | -27.1% | 703,970 | -11.4% | 0.07% | -37.3% |
| Q3 2020 | $4,634,000 | -17.1% | 794,861 | -4.1% | 0.11% | -20.3% |
| Q2 2020 | $5,593,000 | +4.5% | 828,561 | -1.5% | 0.14% | -15.3% |
| Q1 2020 | $5,351,000 | -18.3% | 841,359 | +33.9% | 0.16% | +14.0% |
| Q4 2019 | $6,551,000 | – | 628,360 | – | 0.14% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 814,833 | $60,485,054,000 | 53.20% |
| Palo Alto Investors LP | 2,121,857 | $157,505,000 | 7.79% |
| NEA Management Company, LLC | 2,279,781 | $169,228,000 | 7.65% |
| EcoR1 Capital, LLC | 243,048 | $18,041,000 | 6.01% |
| Redmile Group, LLC | 900,879 | $66,872,000 | 6.00% |
| Opaleye Management Inc. | 140,000 | $10,392,000 | 4.82% |
| PFM Health Sciences, LP | 2,266,756 | $168,261,000 | 4.64% |
| Partner Investment Management, L.P. | 40,798 | $3,028,000 | 4.56% |
| CLIFTON PARK CAPITAL MANAGEMENT, LLC | 826,919 | $61,383,000 | 3.74% |
| Opus Point Partners Management, LLC | 55,988 | $4,156,000 | 3.48% |